Ground News

Don't Just Read the News, Understand It.

biopharmadive.com image

News from biopharmadive.com

See all of biopharmadive.com news coverage in one place. Discover how biopharmadive.com’s media bias informs their coverage and compare with thousands of other news outlets.

Overall, we’ve indexed 229 stories from biopharmadive.com over the past 3 months.

The Ground News media bias check for biopharmadive.com is Center. Scores are assigned by aggregating bias scores from Ad Fontes Media, Media Bias/Fact Check, and All Sides.

biopharmadive.com’s aggregated factuality score is High. Factuality is assigned by combining fact check, credibility, and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about biopharmadive.com

Where is biopharmadive.com located?biopharmadive.com's Website

Media Bias Ratings

Average Bias Rating:

Center

Center

byMedia Bias/Fact Check

Do you diasgree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top biopharmadive.com News

Kennedy names 8 vaccine committee replacements, including COVID shot critic

US Politics · United States

Kennedy names 8 vaccine committee replacements, including COVID shot critic

60% Center coverage: 241 sources

U.S. Health Secretary Robert F. Kennedy Jr. on Wednesday named eight new vaccine policy advisers to replace the panel that he abruptly dismissed earlier this week.See the Story

BioNTech to Buy CureVac in $1.25B Stock Deal That Would Also End mRNA Patent Dispute

Europe · Germany

BioNTech to Buy CureVac in $1.25B Stock Deal That Would Also End mRNA Patent Dispute

47% Center coverage: 28 sources

BioNTech is acquiring CureVac in a deal that brings messenger RNA manufacturing capability and cancer immunotherapy candidates. Analysts say the M&A deal is a way to essentially settle out of court the ongoing mRNA patent dispute between the companies following some recent CureVac legal wins. The post BioNTech to Buy CureVac in $1.25B Stock Deal That Would Also End mRNA Patent Dispute appeared first on MedCity News.See the Story

US FDA approves expanded use of Moderna's RSV vaccine for at-risk adults

FDA · United States

US FDA approves expanded use of Moderna's RSV vaccine for at-risk adults

72% Center coverage: 18 sources

Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening Its Neuropsychiatry Product Portfolio

67% Center coverage: 3 sources

Proposed acquisition expected to accelerate mid- to long-term revenue and cash flow growth and further diversify revenue base.Strengthens Supernus’ leading...Stock Markets See the Story

Parkinson's Discovery Suggests We Could Have an FDA-Approved Treatment Already

67% Center coverage: 3 sources

Researchers have discovered how a surface protein on brain cells, called Aplp1, can play a role in spreading material responsible for Parkinson's disease from cell to cell in the brain.Europe See the Story

FDA clears CSL’s swelling disease drug; Regeneron loses 23andMe auction

100% Center coverage: 1 sources

The agency cleared CSL’s hereditary angioedema drug days after “resource constraints” delayed a rival medicine. Elsewhere, Intellia revealed new data and Lilly beefed up an online service offering access to Zepbound.23andMe · United States Read Article

Could the FDA take an indirect approach to regulate LDTs?

100% Center coverage: 3 sources

Attorneys said many questions remain about the regulation of laboratory developed tests after the FDA lost its legal fight. A recent warning letter could be a clue to future enforcement.Regulation · United States See the Story

FDA to miss approval deadline for Kalvista drug due to ‘resource constraints’

100% Center coverage: 2 sources

A “heavy workload” and “limited resources” have left the agency unable to meet a June 17 deadline to approve a therapy Kalvista has been developing for hereditary angioedema.United States · United States See the Story

AstraZeneca Forms an AI Deal in China; Third Harmonic Advances Liquidation Plans

67% Right coverage: 3 sources

AstraZeneca could spend up to $5.3 billion in a deal to develop oral medicines with CSPC Pharmaceutical. Elsewhere, Insmed cashed in on a stock surge and Third Harmonic kicked off a drug auction.Asia · China See the Story

Next-Generation TKI Approved for Advanced ROS1-Positive Lung Cancer

100% Center coverage: 2 sources

(MedPage Today) -- The FDA approved taletrectinib (Ibtrozi) -- a next-generation oral ROS1 tyrosine kinase inhibitor (TKI) -- for the treatment of adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC)...Pharma · United States See the Story

Bristol Myers Squibb Is Paying $350M to Expand Its Reach in Radiopharmaceuticals to Prostate Cancer

100% Center coverage: 3 sources

Bristol Myers Squibb is licensing global rights to a Philochem program in development for both diagnostic imaging and targeted treatment of prostate cancer. It follows the pharma giant’s entry into radiopharmaceuticals via the $4.1 billion acquisition of RayzeBio last year. The post Bristol Myers Squibb Is Paying $350M to Expand Its Reach in Radiopharmaceuticals to Prostate Cancer appeared first on MedCity News.See the Story

Breaking News Topics Related to biopharmadive.com